Background The aim of the CRASH-2 trial was to assess the eff ects of early administration of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with signifi cant haemorrhage. Tranexamic acid signifi cantly reduced all-cause mortality. Because tranexamic acid is thought to exert its eff ect through inhibition of fi brinolysis, we undertook exploratory analyses of its eff ect on death due to bleeding.
Introduction
The CRASH-2 trial showed that administration of tranexamic acid to adult trauma patients with, or at risk of, signifi cant haemorrhage, within 8 h of injury, signi fi cantly reduces all-cause mortality (relative risk [RR] 0·91, 95% CI 0·85-0·97; p=0·0035) with no apparent increase in vascular occlusive events. 1 As a consequence of this trial, tranexamic acid has been incorporated into trauma treatment protocols worldwide.
Results from the CRASH-2 trial raise some important questions. The trial was motivated by the evidence that tranexamic acid reduces bleeding in patients undergoing elective surgery, and the hypothesised mechanism was inhibition of fi brinolysis leading to improved eff ectiveness of haemostasis. 2 However, no signifi cant diff erence was recorded in transfusion requirements between the tranexamic acid and placebo groups, and the CRASH-2 trial did not measure the eff ect of this drug on fi brinolytic assays. Thus an alternative hypothesis is that tranexamic acid might act by reducing the pro-infl ammatory eff ects of plasmin, rather than by improving haemostasis. 3 There has also been discussion about which trauma patients should be treated with tranexamic acid. The CRASH-2 trial 1 reported the few subgroup analyses that were prespecifi ed in the statistical analysis plan. These analyses assessed the eff ect of tranexamic acid on the primary endpoint of all-cause mortality, according to time since injury, systolic blood pressure, Glasgow coma score, and type of injury. No strong evidence of heterogeneity was recorded for any of these analyses, suggesting that tranexamic acid is likely to be equally eff ective in all the subgroups examined.
The focus on all-cause mortality was appropriate because it is an outcome that matters to patients and one that is not aff ected by the methodological problem of competing risks. 4 However, the eff ect of the trial treatment on the biologically relevant outcome could have been diluted by outcomes on which tranexamic acid might have little or no eff ect. In response to these concerns, we undertook exploratory analyses of the eff ect of tranexamic acid on mortality due to bleeding. We report the same prespecifi ed subgroup analyses but for the outcome that we hypothesise would be most aff ected by this drug, specifi cally mortality due to bleeding.
Methods

Study design and patients
The background to the trial, methods, and baseline characteristics of the randomised patients have been previously reported. 1 Briefl y, we randomly allocated 20 211 adult trauma patients with, or at risk of, signifi cant bleeding who were within 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min followed by infusion of 1 g over 8 h) or matching placebo, with 99·6% follow-up. In most hospitals we used a local pack system for randomisation. After eligibility had been confi rmed and the locally approved consent procedures had been completed, patients were randomly assigned by selection of the lowest numbered treatment pack from a box containing eight numbered packs. Apart from the pack number, the treatment packs were identical. The pack number was recorded on the entry form, which was sent to the Trial Coordinating Centre in London, UK. Hospitals with telephone access used a telephone randomisation service. Both participants and study staff (site investigators and trial coordinating centre staff ) were masked to treatment allocation.
Statistical analysis
The primary outcome was death in hospital within 4 weeks of injury, with cause of death described with the following categories: bleeding, vascular occlusion (myocardial infarction, stroke, and pulmonary embolism), multiorgan failure, head injury, and other.
All analyses were by intention to treat. We examined the eff ect of the trial treatment on death due to bleeding subdivided by four baseline characteristics: (1) time from injury to treatment (≤1, >1-3, >3 h); (2) severity of haemorrhage as assessed by systolic blood pressure (≤75, 76-89, >89 mm Hg); (3) Glasgow coma score (severe 3-8, moderate 9-12, mild 13-15) ; and (4) type of injury (penetrating only, blunt plus blunt and penetrating). These were the same subgroup analyses that were reported previously, but for the outcome of death due to bleeding rather than for all-cause mortality.
Heterogeneity in treatment eff ects across subgroups was assessed by a χ² test. We had prespecifi ed that unless there was strong evidence against the null hypothesis of homogeneity of eff ects (ie, p<0·001), the overall RR would be considered the most reliable guide to the approximate RRs in all subgroups. To test the
N All causes of death Bleeding death Non-bleeding death
Overall 20 127 0·91 (0·85-0·97); p=0·0035 0·85 (0·76-0·96); p=0·0077 0·94 (0·86-1·02); p=0·13 independence of any observed treatment interactions we ran a logistic model including all possible interactions in the four prespecifi ed baseline characteristics and treatment subgroups. A logistic regression was estimated with death due to bleeding as the dependent variable and treatment group and time to treatment as explanatory factors. We included an interaction parameter to allow for a proportional change in the odds ratio (OR) as time to treatment increases. ORs and 95% CIs were estimated for diff erent times to treatment. CIs were calculated with a logistic model with time as a continuous term and an interaction term between time and tranexamic acid. We also ran a model with an interaction term for time to treatment squared to allow for a non-constant proportional change in the OR.
The trial is registered as ISRCTN86750102, ClinicalTrials.gov NCT00375258, and South African Clinical Trial Register/Department of Health DOH-27-0607-1919.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author (IR) had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Of the 3076 deaths from all causes, death due to bleeding accounted for 1063 (35%). The risk of death due to bleeding was signifi cantly reduced with tranexamic acid. 489 of 10 060 (4·9%) patients died because of bleeding in the tranexamic acid group versus 574 of 10 067 (5·7%) in the placebo group (RR 0·85, 95% CI 0·76-0·96; p=0·0077). We noted no signifi cant eff ect on the risk of death for all other (non-bleeding) causes combined (table table 1 ). Table Table 2 shows the baseline characteristics of patients according to time to treatment. Figure Figure 1 shows the results of the subgroup analyses for death due to bleeding. Time to treatment was unknown in nine participants. Treatment given 1 h or less from injury signifi cantly reduced the risk of death due to bleeding (198/3747 [5·3%] in tranexamic acid group vs 286/3704 [7·7%] in placebo group; RR 0·68, 95% CI 0·57-0·82; p<0·0001). Treatment given between 1 and 3 h also reduced the risk of death due to bleeding (147/3037 [4·8%] vs 184/2996 [6·1%]; RR 0·79, 0·64-0·97; p=0·03). Treatment given more than 3 h after injury signifi cantly increased the risk of death due to bleeding (144/3272 [4·4%] vs 103/3362 [3·1%]; RR 1·44, 1·12-1·84; p=0·004). We recorded strong evidence that the eff ect of tranexamic acid on death due to bleeding varied according to time from injury to treatment (p<0·0001). The evidence for interaction remained strong even after adjustment for interactions between the other prespecifi ed baseline characteristics and treatment (p<0·0001; data not shown).
The estimated OR of tranexamic acid on death due to bleeding when given immediately after injury was 0·61 Glasgow coma score
Severe (3-8) Moderate (9-12) Mild (13) (14) (15) χ²=1·275; p=0·53 
Type of injury
1·2 1·4 Tranexamic acid better Tranexamic acid worse (95% CI 0·50-0·74). We estimated that this OR is multiplied by 1·15 (95% CI 1·08-1·23) for every hour that passes since the injury. Figure Figure 2 shows how the OR and 95% CIs vary with time to treatment. The interaction term for time to treatment squared was not signifi cant (OR=0·99; p=0·38). We recorded no evidence of heterogeneity for the subgroup analyses according to systolic blood pressure, Glasgow coma score at randomisation, or type of injury (fi gure 1). We detected no evidence of heterogeneity in the eff ect of tranexamic acid on the risk of non-bleeding deaths (table 1).
Discussion
The eff ect of tranexamic acid on death due to bleeding depends on the time between injury and onset of treatment. Early treatment with this drug seems to be much more eff ective than does late treatment. These results also raise the possibility that late treatment with tranexamic acid might increase the risk of death due to bleeding, although there was no evidence of any increase in all-cause mortality in patients treated after 3 h (table 1) . This fi nding might indicate that patients treated with tranexamic acid beyond 3 h who died from bleeding might otherwise have died from some other non-bleeding cause (competing risks). If late administration does cause harm, this fi nding would be important since many bleeding trauma patients in lowincome and middle-income countries have long prehospital times. Indeed, about a third of trauma patients in the CRASH-2 trial were treated more than 3 h after the injury.
The inclusion criteria in the CRASH-2 trial were entirely clinical, and refl ect the situation that doctors are faced with in clinical practice. Patients were enrolled if the treating physician judged them to have ongoing signifi cant haemorrhage, as evidenced by hypotension or tachycardia, or if they were considered to be at risk of signifi cant haemorrhage. Some of the included patients might not have been actively bleeding. Any such misdiagnosis would have reduced the power of the trial to show an eff ect of tranexamic acid on mortality from bleeding, in which case the large and highly signifi cant reduction in bleeding mortality in patients treated with this drug within 1 h of injury is particularly noteworthy.
Because patients were randomly assigned soon after hospital admission, before the precise anatomical location of bleeding and other injury was known, we were unable to do a stratifi ed analysis based on an anatomical assessment of injury severity. We acknowledge that this omission is a methodological weakness, since such an analysis might provide insight into the mechanism of action of tranexamic acid. However, since this information would not normally be available to treating clinicians, especially in view of the importance of early treatment, the clinical value of a stratifi ed analysis based on anatomical injury severity is small. Data for the time between injury and treatment were available for all but nine trial participants. Because in some cases the injury would not have been witnessed, this interval sometimes had to be estimated and might therefore be inaccurate. However, any inaccuracy would be independent of the trial treatment and therefore should not bias the results. The ascertainment of a death as a bleeding death might also have been inaccurate, but similarly any inaccuracy should be independent of the trial treatment.
In clinical trials, a treatment is not often benefi cial in one subgroup but harmful in another (qualitative interaction), and some trialists recommend that qualitative interactions should generally be disbelieved. 5 The results of our analysis of the eff ect of tranexamic acid on death due to bleeding do, however, satisfy most of the criteria against which the credibility of subgroup results should be judged: 6 time from injury was measured at baseline; the hypothesis that early treatment with tranexamic acid might be more eff ective was prespecifi ed in the trial protocol; the interaction suggests a very low likelihood that chance explains the fi ndings; the interaction remained signifi cant after controlling for the non-signifi cant interactions between treatment and the other prespecifi ed baseline prognostic factors; the subgroup eff ect is large; and a biological rationale supports the interaction. Although this clinical trial was not powered to examine subgroup eff ects, the interaction recorded is large and highly signifi cant. 7 Nevertheless, we prespecifi ed in our trial protocol that the main subgroup analyses would be undertaken for allcause mortality, and not for mortality due to bleeding. Even though we postulated that tranexamic acid would act by reducing bleeding, we focused on all-cause mortality because overall survival is most important to patients. However, in view of the signifi cant reduction in all-cause mortality, most of which was attributable to the eff ect of tranexamic acid on death due to bleeding, and the biological rationale that this drug would act by improving haemostasis, our analyses, although not prespecifi ed, would seem justifi ed. Acute severe trauma is associated with increased fi brinolysis that contributes to an early coagulopathy and increased mortality. 8, 9 Fibrinolysis can be assessed by measurement of fi brin degradation products, which include small protein fragments called D-dimers. Brohi and colleagues 8 showed that D-dimer concentrations are raised in trauma patients at the time of hospital admission (median prehospital time 28 min), with the highest concentrations measured in the most severely injured patients. 8 Similar results were recorded in a 2009 study from Japan that measured fi brin degradation product and D-dimers in 314 severe trauma patients. 10 If this early increased fi brinolysis exacerbates bleeding and increases the risk of death, then we might expect that an antifi brinolytic drug such as tranexamic acid would be most eff ective in this period.
Although we had anticipated that early treatment with tranexamic acid might be most eff ective, the apparent increase in the risk of death due to bleeding in patients treated more than 3 h after the injury is unexpected and cannot readily be explained. It could be a chance fi nding and there might be no real biological eff ect. However, patients in the late phase of trauma can develop thrombotic disseminated intravascular coagulation, and antifi brinolytics could be contraindicated in this period. 10, 11 Although disseminated intravascular coagulation is characterised by fi brin formation and coagulation, the rapid consumption of coagulation proteins can lead to their exhaustion, resulting in uncontrolled bleeding. The need to avoid giving an antifi brinolytic in this late phase was why we restricted trial inclusion to patients who were within 8 h of injury. The possibility that the change to a prothrombotic state might occur sooner than was previously expected is open to debate and needs further research. We should also bear in mind that patients who arrive at hospital many hours after injury are likely to diff er from those who arrive early. For example, there could be an increased prevalence of hypothermia and acidosis. These or other diff erences could explain the decreased effi cacy of tranexamic acid administration when given late.
A 2011 systematic review of randomised controlled trials concluded that tranexamic acid safely reduces mortality in bleeding trauma patients. 12 Our results strongly endorse the importance of early administration of tranexamic acid in bleeding trauma patients and suggest that trauma systems should be confi gured to facilitate this recommendation (panel panel). In patients presenting late (several hours after injury) the clinician should be more cautious and make an assessment of the individual benefi ts and risks of this treatment, since the drug is likely to be much less eff ective and possibly even harmful. To the extent that our subgroup analyses are consistent with the results of studies showing an early increased fi brinolytic coagulopathy, they support the hypothesis that tranexamic acid acts through the inhibition of fi brinolysis with improved haemostasis.
Future research using the CRASH-2 trial data will develop a prognostic model to predict death due to bleeding. 13 This model will facilitate further analysis of the eff ect of tranexamic acid according to baseline risk of haemorrhage death.
Panel: Research in context
Systematic review A 2011 Cochrane systematic review 12 of antifi brinolytic drugs for acute traumatic injury identifi ed two randomised trials of tranexamic acid in bleeding trauma patients, involving 20 451 patients. The review concluded that tranexamic acid safely reduces mortality in bleeding trauma patients without increasing the risk of adverse events.
Interpretation
Our results emphasise the importance of early administration of tranexamic acid and the need for caution in patients presenting several hours after the injury.
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